Sign in or create an account to add this stock to your watchlist.
About Boston Scientific (NYSE:BSX)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:BSX
CUSIP10113710
Phone508-683-4000
Debt
Debt-to-Equity Ratio0.68
Current Ratio0.82
Quick Ratio0.59
Price-To-Earnings
Trailing P/E Ratio24.06
Forward P/E Ratio21.81
P/E Growth2.16
Sales & Book Value
Annual Sales$9.05 billion
Price / Sales4.62
Cash Flow$1.8944 per share
Price / Cash16.00
Book Value$5.09 per share
Price / Book5.95
Profitability
EPS (Most Recent Fiscal Year)$1.26
Net Income$105 million
Net Margins1.21%
Return on Equity25.10%
Return on Assets9.63%
Miscellaneous
Employees29,000
Outstanding Shares1,379,810,000
Boston Scientific (NYSE:BSX) Frequently Asked Questions
What is Boston Scientific's stock symbol?
Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."
How were Boston Scientific's earnings last quarter?
Boston Scientific (NYSE:BSX) announced its quarterly earnings data on Wednesday, April, 25th. The medical equipment provider reported $0.33 EPS for the quarter, topping analysts' consensus estimates of $0.32 by $0.01. The medical equipment provider earned $2.38 billion during the quarter, compared to analysts' expectations of $2.34 billion. Boston Scientific had a return on equity of 25.10% and a net margin of 1.21%. The firm's quarterly revenue was up 10.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.29 earnings per share. View Boston Scientific's Earnings History.
When is Boston Scientific's next earnings date?
What guidance has Boston Scientific issued on next quarter's earnings?
Boston Scientific updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided EPS guidance of $1.37-1.41 for the period, compared to the Thomson Reuters consensus estimate of $1.37. The company issued revenue guidance of $9.75-9.90 billion (+5-7% organic), compared to the consensus revenue estimate of $9.75 billion.Boston Scientific also updated its Q2 guidance to $0.33-0.35 EPS.
What price target have analysts set for BSX?
21 brokers have issued 12 month price targets for Boston Scientific's shares. Their predictions range from $27.00 to $36.00. On average, they expect Boston Scientific's stock price to reach $32.1429 in the next twelve months. View Analyst Ratings for Boston Scientific.
What are Wall Street analysts saying about Boston Scientific stock?
Here are some recent quotes from research analysts about Boston Scientific stock:
- 1. According to Zacks Investment Research, "Boston Scientific posted an impressive first quarter on growth across all business lines and geographies. The 2018 view also paints a bright picture for the near term. Boston Scientific achieved clinical milestones for Ranger Drug Coated Balloon and WATCHMAN Left Atrial Appendage Closure device. Also, post the suspension of Lotus valve in Europe, ACURATE TAVR valve platform continues to build momentum. During the quarter, Boston Scientific announced several strategic acquisitions including NxThera and nVision in Urology and Pelvic Health, EmCision in Endoscopy, Securus in EP and Millipede in Structural Heart. This inorganic expansion plan bode well for the stocks operational growth. Over the past three months, Boston Scientific outperformed its industry. On the flip side, a delay in the relaunch of the Lotus range of heart devices is expected to hamper sales in 2018 too." (5/21/2018)
- 2. Canaccord Genuity analysts commented, "We reiterate our BUY rating and $35 year-end target price on shares of BSX. Our key takeaways from our meeting last week with senior management in San Francisco (as well as incremental tidbits we gleaned over the weekend at the North American Neuromodulation Society (NANS) conference in Vegas) support our general hypothesis on the stock: We expect BSX to deliver top- and bottom-line growth rates above the large-cap medical device peer group average over the 2018-2020 timeframe." (1/17/2018)
- 3. Jefferies Group LLC analysts commented, "We are re-establishing estimates, a Buy rating and $14.00 PT for Flex Pharma. Flex is developing FLX-787, an innovative anti-cramp drug in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and multiple sclerosis (MS). We believe CMT , on which we base our PT , has the highest chance of success. We anticipate Ph2 data in 1Q’18 (MS) and 3Q’18 (ALS, CMT). In 2Q’16, Flex launched HOTSHOT , a consumer beverage for exercise- associated muscle cramps that works via the same mechanisms as FLX-787." (9/7/2017)
Who are some of Boston Scientific's key competitors?
Some companies that are related to Boston Scientific include 3M (MMM), Stryker (SYK), Becton Dickinson (BDX), Fresenius (FSNUY), Baxter International (BAX), Abiomed (ABMD), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Penumbra (PEN), Cantel Medical (CMD) and Globus Medical (GMED).
Who are Boston Scientific's key executives?
Boston Scientific's management team includes the folowing people:
- Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 53)
- Mr. Daniel J. Brennan, Exec. VP & CFO (Age 52)
- Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 54)
- Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 45)
- Mr. Edward F. Mackey, Exec. VP of Operations (Age 55)
Has Boston Scientific been receiving favorable news coverage?
News articles about BSX stock have been trending somewhat positive on Sunday, Accern reports. The research group identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Boston Scientific earned a coverage optimism score of 0.14 on Accern's scale. They also assigned media stories about the medical equipment provider an impact score of 45.43 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Boston Scientific's major shareholders?
Boston Scientific's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.70%), Bollard Group LLC (2.44%), Artisan Partners Limited Partnership (1.94%), Northern Trust Corp (1.08%), Wells Fargo & Company MN (0.93%) and Newport Trust Co (0.78%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, John Bradley Sorenson, Joseph Michael Fitzgerald, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific.
Which institutional investors are selling Boston Scientific stock?
BSX stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Boston Partners, Artisan Partners Limited Partnership, Prudential Financial Inc., State of Tennessee Treasury Department, Natixis, Russell Investments Group Ltd. and Swiss National Bank. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, John Bradley Sorenson, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael P Phalen, Supratim Bose, Timothy A Pratt and Wendy Carruthers. View Insider Buying and Selling for Boston Scientific.
Which institutional investors are buying Boston Scientific stock?
BSX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Eaton Vance Management, Cannell Peter B & Co. Inc., Bodenholm Capital AB, Point72 Asset Management L.P., Wells Fargo & Company MN, Anchor Capital Advisors LLC and Royal Bank of Canada. View Insider Buying and Selling for Boston Scientific.
How do I buy shares of Boston Scientific?
Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Boston Scientific's stock price today?
One share of BSX stock can currently be purchased for approximately $30.31.
How big of a company is Boston Scientific?
Boston Scientific has a market capitalization of $41.82 billion and generates $9.05 billion in revenue each year. The medical equipment provider earns $105 million in net income (profit) each year or $1.26 on an earnings per share basis. Boston Scientific employs 29,000 workers across the globe.
How can I contact Boston Scientific?
Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]
MarketBeat Community Rating for Boston Scientific (BSX)
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe BSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Boston Scientific (NYSE:BSX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
21 Wall Street analysts have issued ratings and price targets for Boston Scientific in the last 12 months. Their average twelve-month price target is $32.1429, suggesting that the stock has a possible upside of 6.05%. The high price target for BSX is $36.00 and the low price target for BSX is $27.00. There are currently 3 hold ratings, 15 buy ratings and 3 strong buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 2.95 | 2.83 | 2.78 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
15 Buy Rating(s)
3 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
3 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
13 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $32.1429 | $31.8571 | $30.8824 | $31.10 |
| Price Target Upside: | 6.05% upside | 8.06% upside | 16.63% upside | 11.83% upside |
Boston Scientific (NYSE:BSX) Consensus Price Target History
Boston Scientific (NYSE:BSX) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Boston Scientific (NYSE:BSX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Boston Scientific (NYSE BSX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.73%
Institutional Ownership Percentage: 89.38%
Boston Scientific (NYSE BSX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/17/2018 | Eric Francis Yves Thepaut | SVP | Sell | 20,015 | $30.15 | $603,452.25 | |  |
| 5/10/2018 | Arthur C Butcher | SVP | Sell | 7,500 | $30.06 | $225,450.00 | 12,484 | |
| 5/7/2018 | Kevin J. Ballinger | EVP | Sell | 31,056 | $30.00 | $931,680.00 | | |
| 5/1/2018 | David A Pierce | EVP | Sell | 5,000 | $28.80 | $144,000.00 | 29,201 | |
| 4/2/2018 | David A Pierce | EVP | Sell | 5,000 | $27.22 | $136,100.00 | | |
| 3/20/2018 | John Bradley Sorenson | SVP | Sell | 2,200 | $27.63 | $60,786.00 | 34,636 | |
| 3/19/2018 | Daniel J Brennan | CFO | Sell | 60,209 | $27.87 | $1,678,024.83 | 299,644 | |
| 3/14/2018 | Kevin J Ballinger | EVP | Sell | 42,803 | $28.32 | $1,212,180.96 | | |
| 3/5/2018 | John Bradley Sorenson | SVP | Sell | 1,950 | $27.43 | $53,488.50 | | |
| 2/28/2018 | David A Pierce | SVP | Sell | 4,508 | $27.54 | $124,150.32 | | |
| 2/21/2018 | David A Pierce | SVP | Sell | 16,286 | $27.00 | $439,722.00 | | |
| 2/9/2018 | Maulik Nanavaty | SVP | Sell | 15,568 | $25.38 | $395,115.84 | | |
| 2/7/2018 | Joseph Michael Fitzgerald | EVP | Sell | 85,227 | $26.48 | $2,256,810.96 | | |
| 2/1/2018 | David A Pierce | SVP | Sell | 5,152 | $27.43 | $141,319.36 | 29,353 | |
| 1/11/2018 | David A Pierce | SVP | Sell | 8,763 | $27.74 | $243,085.62 | 24,201 | |
| 1/9/2018 | David A Pierce | SVP | Sell | 5,152 | $27.00 | $139,104.00 | 38,116 | |
| 12/29/2017 | Michael P Phalen | EVP | Sell | 15,835 | $25.25 | $399,833.75 | | |
| 12/29/2017 | Michael P. Phalen | EVP | Sell | 15,835 | $25.25 | $399,833.75 | | |
| 12/1/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $26.04 | $260,400.00 | 154,681 | |
| 12/1/2017 | Valley Gold Master Fund L Sun | Insider | Buy | 27,431 | $0.44 | $12,069.64 | | |
| 11/29/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $26.66 | $413,230.00 | | |
| 11/28/2017 | Valley Gold Master Fund L Sun | Insider | Buy | 408,006 | $0.45 | $183,602.70 | | |
| 11/1/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $28.22 | $282,200.00 | 164,681 | |
| 10/30/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $28.42 | $440,510.00 | | |
| 10/4/2017 | Supratim Bose | EVP | Sell | 347,137 | $29.12 | $10,108,629.44 | | |
| 10/2/2017 | Timothy A Pratt | EVP | Sell | 11,061 | $29.24 | $323,423.64 | 174,681 | |
| 9/29/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $28.72 | $445,160.00 | | |
| 9/1/2017 | Timothy A Pratt | EVP | Sell | 10,104 | $27.46 | $277,455.84 | 185,742 | |
| 8/31/2017 | Maulik Nanavaty | SVP | Sell | 57,031 | $27.28 | $1,555,805.68 | | |
| 8/30/2017 | Maulik Nanavaty | SVP | Sell | 27,031 | $27.08 | $731,999.48 | | |
| 8/29/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $26.87 | $416,485.00 | | |
| 8/3/2017 | Wendy Carruthers | SVP | Sell | 12,433 | $26.75 | $332,582.75 | | |
| 8/2/2017 | John Bradley Sorenson | SVP | Sell | 7,900 | $26.37 | $208,323.00 | 21,680 | |
| 8/1/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $26.67 | $266,700.00 | 195,846 | |
| 7/31/2017 | John Bradley Sorenson | SVP | Sell | 2,100 | $27.15 | $57,015.00 | 18,880 | |
| 7/31/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $27.13 | $420,515.00 | | |
| 7/11/2017 | Daniel J Brennan | CFO | Sell | 92,158 | $27.48 | $2,532,501.84 | 235,421 | |
| 7/3/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $27.87 | $278,700.00 | 205,846 | |
| 6/29/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $28.02 | $434,310.00 | | |
| 6/9/2017 | David A Pierce | SVP | Sell | 13,562 | $28.00 | $379,736.00 | 33,701 | |
| 6/2/2017 | David A Pierce | SVP | Sell | 2,972 | $27.70 | $82,324.40 | 28,572 | |
| 6/1/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $27.13 | $271,300.00 | 215,846 | |
| 5/30/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $27.25 | $422,375.00 | | |
| 5/17/2017 | Kevin J. Ballinger | EVP | Sell | 28,864 | $26.14 | $754,504.96 | | |
| 5/1/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $26.37 | $263,700.00 | 225,846 | |
| 4/26/2017 | David A Pierce | SVP | Sell | 10,250 | $26.00 | $266,500.00 | 35,850 | |
| 4/26/2017 | Michael P. Phalen | EVP | Sell | 34,773 | $26.00 | $904,098.00 | | |
| 4/10/2017 | John Bradley Sorenson | SVP | Sell | 2,950 | $24.66 | $72,747.00 | 20,980 | |
| 4/3/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $24.87 | $248,700.00 | 235,846 | |
| 3/29/2017 | Michael P. Phalen | EVP | Sell | 79,045 | $24.55 | $1,940,554.75 | | |
| 3/3/2017 | David A Pierce | SVP | Sell | 25,012 | $25.01 | $625,550.12 | 25,600 | |
| 3/3/2017 | Timothy A Pratt | EVP | Sell | 23,540 | $25.01 | $588,735.40 | 245,846 | |
| 2/27/2017 | David A Pierce | SVP | Sell | 3,417 | $24.84 | $84,878.28 | 34,267 | |
| 2/27/2017 | Timothy A Pratt | EVP | Sell | 4,832 | $24.84 | $120,026.88 | 248,758 | |
| 2/7/2017 | Keith D Dawkins | EVP | Sell | 80,783 | $25.21 | $2,036,539.43 | 75,864 | |
| 1/9/2017 | David A Pierce | SVP | Sell | 10,232 | $22.24 | $227,559.68 | 25,600 | |
| 1/9/2017 | Timothy A Pratt | EVP | Sell | 6,195 | $22.24 | $137,776.80 | 231,273 | |
| 12/1/2016 | Timothy A Pratt | EVP | Sell | 26,726 | $20.48 | $547,348.48 | 260,430 | |
| 8/11/2016 | John Bradley Sorenson | SVP | Sell | 2,500 | $23.90 | $59,750.00 | 12,615 | |
| 8/1/2016 | Michael F Mahoney | CEO | Sell | 44,400 | $24.44 | $1,085,136.00 | 1,388,177 | |
| 8/1/2016 | Timothy A Pratt | EVP | Sell | 24,000 | $24.46 | $587,040.00 | 287,495 | |
| 7/20/2016 | David A Pierce | SVP | Sell | 2,480 | $24.03 | $59,594.40 | 28,080 | |
| 7/20/2016 | Michael P. Phalen | EVP | Sell | 35,000 | $24.03 | $841,050.00 | | |
| 6/1/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $22.69 | $2,269,000.00 | 1,532,577 | |
| 6/1/2016 | Timothy A Pratt | EVP | Sell | 24,229 | $22.66 | $549,029.14 | 301,724 | |
| 5/11/2016 | John Bradley Sorenson | SVP | Sell | 2,800 | $22.15 | $62,020.00 | 15,115 | |
| 5/10/2016 | Keith D Dawkins | EVP | Sell | 80,000 | $22.15 | $1,772,000.00 | 150,227 | |
| 5/6/2016 | Jeffrey B Mirviss | SVP | Sell | 24,659 | $21.94 | $541,018.46 | 71,975 | |
| 5/3/2016 | Joseph Michael Fitzgerald | EVP | Sell | 79,960 | $21.81 | $1,743,927.60 | 92,020 | |
| 5/2/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $22.12 | $2,212,000.00 | 1,632,577 | |
| 5/2/2016 | Timothy A Pratt | EVP | Sell | 24,000 | $21.93 | $526,320.00 | 308,724 | |
| 4/27/2016 | Kevin J Ballinger | SVP | Sell | 111,807 | $21.62 | $2,417,267.34 | 83,600 | |
| 4/27/2016 | Timothy A Pratt | EVP | Sell | 39,927 | $21.40 | $854,437.80 | 291,724 | |
| 4/4/2016 | Jeffrey B Mirviss | SVP | Sell | 18,422 | $19.00 | $350,018.00 | 96,634 | |
| 4/1/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $18.90 | $1,890,000.00 | 1,732,577 | |
| 4/1/2016 | Timothy A Pratt | EVP | Sell | 24,000 | $18.73 | $449,520.00 | 355,651 | |
| 3/11/2016 | Kevin J Ballinger | SVP | Sell | 16,705 | $18.00 | $300,690.00 | 46,970 | |
| 3/8/2016 | Karen Prange | SVP | Sell | 14,747 | $17.27 | $254,680.69 | 38,395 | |
| 3/2/2016 | Michael P. Phalen | EVP | Sell | 10,665 | $17.17 | $183,118.05 | 89,309 | |
| 3/1/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $16.96 | $1,696,000.00 | 1,832,577 | |
| 3/1/2016 | Timothy A Pratt | EVP | Sell | 15,068 | $16.97 | $255,703.96 | 338,651 | |
| 2/29/2016 | Kevin J. Ballinger | SVP | Sell | 2,114 | $17.17 | $36,297.38 | | |
| 2/29/2016 | Michael P. Phalen | EVP | Sell | 1,819 | $17.19 | $31,268.61 | | |
| 2/25/2016 | Daniel J Brennan | CFO | Sell | 103,211 | $17.22 | $1,777,293.42 | 202,659 | |
| 2/25/2016 | Kevin J. Ballinger | SVP | Sell | 1,903 | $17.48 | $33,264.44 | | |
| 2/25/2016 | Michael P. Phalen | EVP | Sell | 34,106 | $17.28 | $589,351.68 | | |
| 2/17/2016 | Kevin J. Ballinger | SVP | Sell | 7,616 | $17.37 | $132,289.92 | | |
| 2/12/2016 | Charles J Dockendorff | Director | Buy | 30,000 | $16.49 | $494,700.00 | 41,598 | |
| 2/8/2016 | Karen Prange | SVP | Sell | 6,216 | $16.05 | $99,766.80 | 23,647 | |
| 1/8/2016 | Timothy A Pratt | EVP | Sell | 7,160 | $17.67 | $126,517.20 | 303,776 | |
| 1/7/2016 | Kevin J Ballinger | SVP | Sell | 19,059 | $17.73 | $337,916.07 | 30,323 | |
| 1/5/2016 | Jeffrey B Mirviss | SVP | Sell | 9,953 | $18.00 | $179,154.00 | 82,535 | |
| 12/1/2015 | Timothy A. Pratt | EVP | Sell | 24,000 | $18.43 | $442,320.00 | 282,295 | |
| 11/16/2015 | Ernest Mario | Director | Sell | 125,000 | $17.63 | $2,203,750.00 | 86,032 | |
| 11/9/2015 | John Bradley Sorenson | SVP | Sell | 4,469 | $18.68 | $83,480.92 | 5,605 | |
| 11/9/2015 | Joseph Michael Fitzgerald | EVP | Sell | 26,220 | $18.58 | $487,167.60 | 103,925 | |
| 11/5/2015 | Timothy A Pratt | EVP | Sell | 19,598 | $19.00 | $372,362.00 | 289,295 | |
| 10/28/2015 | Jeffrey B Mirviss | SVP | Sell | 9,492 | $18.00 | $170,856.00 | 81,262 | |
| 10/28/2015 | Timothy A Pratt | EVP | Sell | 3,500 | $18.00 | $63,000.00 | 315,893 | |
| 10/5/2015 | Timothy A Pratt | EVP | Sell | 3,500 | $17.34 | $60,690.00 | 319,393 | |
| 10/1/2015 | Timothy A. Pratt | EVP | Sell | 17,000 | $16.33 | $277,610.00 | 322,893 | |
| 8/21/2015 | John E Abele | Director | Buy | 200,000 | $16.77 | $3,354,000.00 | 92,983 | |
| 8/19/2015 | John E Abele | Director | Buy | 200,000 | $17.48 | $3,496,000.00 | 92,983 | |
| 8/17/2015 | John E Abele | Director | Buy | 100,000 | $17.50 | $1,750,000.00 | | |
| 7/7/2015 | Karen Prange | SVP | Sell | 17,456 | $17.66 | $308,272.96 | | |
| 5/29/2015 | Maulik Nanavaty | SVP | Sell | 71,558 | $18.52 | $1,325,254.16 | | |
| 5/28/2015 | Wendy Carruthers | SVP | Sell | 42,281 | $17.91 | $757,252.71 | | |
| 5/18/2015 | Ernest Mario | Director | Sell | 50,000 | $18.09 | $904,500.00 | | |
| 5/14/2015 | John E Sununu | Director | Sell | 10,000 | $17.87 | $178,700.00 | | |
| 5/11/2015 | John Bradley Sorenson | SVP | Sell | 8,735 | $17.49 | $152,775.15 | | |
| 3/20/2015 | David A Pierce | SVP | Sell | 18,050 | $18.00 | $324,900.00 | | |
| 3/20/2015 | Michael P Phalen | EVP | Sell | 46,085 | $17.94 | $826,764.90 | | |
| 3/16/2015 | Michael P Phalen | EVP | Sell | 30,022 | $17.18 | $515,777.96 | | |
| 3/13/2015 | John Bradley Sorenson | SVP | Sell | 3,830 | $16.84 | $64,497.20 | | |
| 3/9/2015 | David A Pierce | SVP | Sell | 2,561 | $16.54 | $42,358.94 | | |
| 3/3/2015 | David A Pierce | SVP | Sell | 8,983 | $16.79 | $150,824.57 | | |
| 3/3/2015 | Michael P Phalen | EVP | Sell | 12,768 | $16.79 | $214,374.72 | | |
| 2/27/2015 | David A Pierce | SVP | Sell | 19,046 | $16.80 | $319,972.80 | | |
| 2/27/2015 | Michael P Phalen | EVP | Sell | 1,819 | $16.80 | $30,559.20 | | |
| 2/19/2015 | David A Pierce | SVP | Sell | 11,958 | $16.46 | $196,828.68 | | |
| 2/19/2015 | Michael P Phalen | EVP | Sell | 13,188 | $16.44 | $216,810.72 | | |
| 2/10/2015 | Joseph Michael Fitzgerald | EVP | Sell | 61,208 | $14.66 | $897,309.28 | | |
| 2/9/2015 | David A Pierce | SVP | Sell | 5,000 | $14.66 | $73,300.00 | | |
| 2/6/2015 | Kevin J Ballinger | SVP | Sell | 21,408 | $15.06 | $322,404.48 | | |
| 1/20/2015 | Michael P Phalen | EVP | Sell | 10,000 | $14.54 | $145,400.00 | | |
| 1/8/2015 | David A Pierce | SVP | Sell | 18,612 | $14.31 | $266,337.72 | | |
| 1/8/2015 | Michael P Phalen | EVP | Sell | 27,589 | $14.31 | $394,798.59 | | |
| 1/5/2015 | Michael P Phalen | EVP | Sell | 10,000 | $13.75 | $137,500.00 | | |
| 12/10/2014 | Karen Prange | SVP | Sell | 19,753 | $12.64 | $249,677.92 | | |
| 12/8/2014 | David A Pierce | SVP | Sell | 5,000 | $12.90 | $64,500.00 | | |
| 12/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.96 | $129,600.00 | | |
| 11/28/2014 | Michael F Mahoney | CEO | Buy | 11,700 | $12.89 | $150,813.00 | | |
| 11/10/2014 | Edward J Ludwig | Director | Buy | 10,000 | $13.38 | $133,800.00 | | |
| 11/5/2014 | John E Sununu | Director | Sell | 8,997 | $13.38 | $120,379.86 | | |
| 11/3/2014 | Ernest Mario | Director | Sell | 10,000 | $13.30 | $133,000.00 | | |
| 10/8/2014 | Ernest Mario | Director | Sell | 10,000 | $12.06 | $120,600.00 | | |
| 9/2/2014 | Ernest Mario | Director | Sell | 10,000 | $12.60 | $126,000.00 | | |
| 8/15/2014 | Michael P Phalen | EVP | Sell | 11,471 | $12.58 | $144,305.18 | | |
| 8/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.58 | $125,800.00 | | |
| 7/30/2014 | David A Pierce | SVP | Sell | 157 | $12.97 | $2,036.29 | | |
| 7/15/2014 | Michael P Phalen | EVP | Sell | 67,500 | $13.04 | $880,200.00 | | |
| 7/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.95 | $129,500.00 | | |
| 6/16/2014 | Michael P Phalen | EVP | Sell | 13,500 | $13.02 | $175,770.00 | | |
| 6/2/2014 | Ernest Mario | Director | Sell | 10,000 | $12.88 | $128,800.00 | | |
| 5/15/2014 | Michael Phalen | EVP | Sell | 13,500 | $12.76 | $172,260.00 | 127,486 | |
| 5/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.58 | $125,800.00 | 317,855 | |
| 4/15/2014 | Michael Phalen | EVP | Sell | 13,500 | $13.25 | $178,875.00 | 127,486 | |
| 4/1/2014 | Ernest Mario | Director | Sell | 10,000 | $13.55 | $135,500.00 | 327,855 | |
| 3/17/2014 | Michael Phalen | EVP | Sell | 13,500 | $13.05 | $176,175.00 | 127,486 | |
| 3/6/2014 | David Pierce | SVP | Sell | 5,316 | $13.44 | $71,447.04 | 43,161 | |
| 3/6/2014 | Michael Phalen | EVP | Sell | 7,281 | $13.44 | $97,856.64 | 127,486 | |
| 2/27/2014 | David Pierce | SVP | Sell | 2,057 | $13.29 | $27,337.53 | 47,990 | |
| 2/27/2014 | Michael Phalen | EVP | Sell | 3,166 | $13.29 | $42,076.14 | 130,848 | |
| 2/21/2014 | David Pierce | SVP | Sell | 3,199 | $13.22 | $42,290.78 | 25,600 | |
| 2/21/2014 | Michael Phalen | EVP | Sell | 3,222 | $13.22 | $42,594.84 | 84,300 | |
| 2/18/2014 | Michael Phalen | EVP | Sell | 13,500 | $13.30 | $179,550.00 | 87,522 | |
| 2/13/2014 | Kristina Johnson | Director | Sell | 18,000 | $13.01 | $234,180.00 | 3,124 | |
| 2/6/2014 | Ernest Mario | Director | Sell | 17,104 | $12.80 | $218,931.20 | 347,855 | |
| 2/3/2014 | Ernest Mario | Director | Sell | 10,000 | $13.19 | $131,900.00 | 364,959 | |
| 1/6/2014 | Ernest Mario | Director | Sell | 10,000 | $12.50 | $125,000.00 | 374,959 | |
| 12/26/2013 | Ernest Mario | Director | Sell | 10,000 | $12.06 | $120,600.00 | 384,959 | |
| 11/26/2013 | Jeffrey Capello | CFO | Sell | 85,106 | $11.82 | $1,005,952.92 | 109,042 | |
| 11/11/2013 | Jeffrey Mirviss | SVP | Sell | 26,000 | $11.91 | $309,660.00 | 39,190 | |
| 8/29/2013 | Jeffrey Capello | CFO | Sell | 525,000 | $10.68 | $5,607,000.00 | 147,447 | |
| 8/16/2013 | Joseph Michael Fitzgerald | SVP | Sell | 9,202 | $11.02 | $101,406.04 | 93,191 | |
| 8/14/2013 | Kevin Ballinger | SVP | Sell | 38,171 | $11.28 | $430,568.88 | 73,519 | |
| 5/31/2013 | Jeffrey B Mirviss | SVP | Sell | 10,941 | $9.37 | $102,517.17 | | |
| 5/30/2013 | Wendy Carruthers | SVP | Sell | 25,001 | $9.16 | $229,009.16 | | |
| 5/29/2013 | Nelda J Connors | Director | Sell | 24,116 | $9.17 | $221,143.72 | | |
| 5/6/2013 | Ernest Mario | Director | Buy | 30,000 | $7.76 | $232,800.00 | | |
| 11/13/2012 | Nj Nicholas Jr | Director | Buy | 20,000 | $5.28 | $105,600.00 | | |
| 11/9/2012 | Nj Nicholas Jr | Director | Buy | 25,000 | $5.17 | $129,250.00 | | |
| 8/6/2012 | Ernest Mario | Director | Buy | 32,000 | $5.29 | $169,280.00 | | |
(Data available from 1/1/2013 forward)
Boston Scientific (NYSE BSX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Boston Scientific (BSX) Expected to Post Quarterly Sales of $2.47 Billion
www.americanbankingnews.com - May 26 at 4:21 AM |
 | Boston Scientific (BSX) Up 3.5% Since Earnings Report: Can It Continue?
finance.yahoo.com - May 25 at 3:37 PM |
| Devices reduce trips to doctor’s office
finance.yahoo.com - May 25 at 10:21 AM |
| Veeva Systems (VEEV) Beats Q1 Earnings Estimates, Raises View
finance.yahoo.com - May 25 at 10:21 AM |
| Here's Why You Should Buy Boston Scientific (BSX) Stock Now
finance.yahoo.com - May 24 at 3:40 PM |
| Boston Scientific (BSX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 24 at 12:42 PM |
 | Here's Why You Should Buy Boston Scientific (BSX) Stock Now
www.zacks.com - May 24 at 10:45 AM |
| $0.34 Earnings Per Share Expected for Boston Scientific (BSX) This Quarter
www.americanbankingnews.com - May 24 at 5:15 AM |
| Boston Scientific (BSX) SVP Eric Francis Yves Thepaut Sells 20,015 Shares
www.americanbankingnews.com - May 18 at 7:39 PM |
| Boston Scientific (BSX) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 18 at 4:51 PM |
| BP, Boston Scientific, Madison Square Garden & Dillard's
finance.yahoo.com - May 17 at 3:35 PM |
| Q2 2018 EPS Estimates for Boston Scientific (BSX) Lowered by Analyst
www.americanbankingnews.com - May 17 at 8:00 AM |
 | A Quick Snapshot of Boston Scientific's Rhythm Management & Neuro Segment
www.forbes.com - May 16 at 3:40 PM |
 | Boston Scientific To Present At BOA Merrill Lynch Conference; Webcast At 8:00 AM
www.nasdaq.com - May 16 at 11:07 AM |
| Zacks.com highlights: General Motors, Boston Scientific, Lam Research, NRG Energy and Celanese
finance.yahoo.com - May 16 at 11:07 AM |
| Boston Scientific Announces Schedule of Presentations at EuroPCR 2018
finance.yahoo.com - May 16 at 11:07 AM |
 | BRIEF-Jana Partners LLC Takes Sole Share Stake In Allergan, Boston Scientific
www.reuters.com - May 15 at 11:20 AM |
 | JANA Shows New Stakes in Apple (AAPL), Boston Scientific (BSX), Dropbox (DBX), iQIYI (IQ) (more..) -13F
www.streetinsider.com - May 15 at 11:20 AM |
| ’60 Minutes’ Shines Harsh Light on Boston Scientific’s Gynecological Mesh
finance.yahoo.com - May 14 at 3:37 PM |
 | ’60 Minutes’ Shines Harsh Light on Boston Scientific’s Gynecological Mesh
investorplace.com - May 14 at 11:54 AM |
| Boston Scientific To Participate In 34th Annual Strategic decisions Conference
finance.yahoo.com - May 14 at 11:46 AM |
 | Boston Scientific down 2% premarket after critical 60 minutes report
seekingalpha.com - May 14 at 7:52 AM |
| Boston Scientific Announces Real-World Data Demonstrating Success Of SMART Pass On The S-ICD System
finance.yahoo.com - May 12 at 11:02 AM |
| Boston Scientific (BSX) SVP Sells $225,450.00 in Stock
www.americanbankingnews.com - May 11 at 8:24 PM |
| Boston Scientific (BSX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 11 at 7:05 PM |
| Boston Scientific subject of 60 minutes report May 13
seekingalpha.com - May 11 at 11:41 AM |
| Will Boston Scientific Corporation (NYSE:BSX) Continue To Underperform Its Industry?
finance.yahoo.com - May 10 at 10:53 AM |
| Insider Selling: Boston Scientific (BSX) EVP Sells 31,056 Shares of Stock
www.americanbankingnews.com - May 8 at 7:39 PM |
| Boston Scientific (BSX) Expected to Announce Quarterly Sales of $2.47 Billion
www.americanbankingnews.com - May 8 at 2:10 AM |
| Boston Scientific To Participate In Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 7 at 3:40 PM |
| Brokerages Anticipate Boston Scientific (BSX) Will Announce Earnings of $0.34 Per Share
www.americanbankingnews.com - May 6 at 8:05 PM |
| Boston Scientific (BSX) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - May 3 at 10:05 PM |
| MARKETS: Stocks are selling off on the ISM miss, which also reveals problems in the factory sector
finance.yahoo.com - May 3 at 3:38 PM |
| Boston Scientific (BSX) EVP David A. Pierce Sells 5,000 Shares
www.americanbankingnews.com - May 2 at 4:40 PM |
| Boston Scientific (BSX) PT Raised to $34.00 at Citigroup
www.americanbankingnews.com - May 1 at 10:42 AM |
| Boston Scientific Closes NxThera Acquisition
finance.yahoo.com - April 30 at 9:40 AM |
| Boston Scientific (BSX) Expected to Earn FY2018 Earnings of $1.39 Per Share
www.americanbankingnews.com - April 30 at 4:01 AM |
| FY2018 EPS Estimates for Boston Scientific (BSX) Boosted by Oppenheimer
www.americanbankingnews.com - April 30 at 4:01 AM |
| Research Analysts Set Expectations for Boston Scientific's Q2 2018 Earnings (BSX)
www.americanbankingnews.com - April 30 at 2:14 AM |
| Boston Scientific (BSX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 29 at 11:46 AM |
 | Prosthetic Heart Valves 2018-2022: Global Market Analysis & Forecasts with Abbott, Boston Scientific, Edwards ...
www.businesswire.com - April 27 at 3:30 PM |
| Earnings Reaction History: Boston Scientific Corporation, 33.3% Follow-Through Indicator, 3.4% Sensitive
www.nasdaq.com - April 27 at 3:30 PM |
| BRIEF-Boston Scientific Announces Q1 GAAP Earnings Per Share $0.21
www.reuters.com - April 27 at 3:30 PM |
| Leerink Swann Research Analysts Cut Earnings Estimates for Boston Scientific (BSX)
www.americanbankingnews.com - April 27 at 8:04 AM |
| Q2 2018 Earnings Forecast for Boston Scientific Issued By Oppenheimer (BSX)
www.americanbankingnews.com - April 27 at 7:58 AM |
| Boston Scientific Forecasted to Post Q2 2018 Earnings of $0.34 Per Share (BSX)
www.americanbankingnews.com - April 27 at 7:58 AM |
| Thermo Fisher Scientific’s 1Q18 Sales Beat Estimates, Stock Up
finance.yahoo.com - April 26 at 3:37 PM |
| Boston Scientific (BSX) Given New $34.00 Price Target at Raymond James
www.americanbankingnews.com - April 26 at 12:27 PM |
| Boston Scientific (BSX) Rating Reiterated by Jefferies Group
www.americanbankingnews.com - April 26 at 11:52 AM |
| Boston Scientific (BSX) Price Target Increased to $36.00 by Analysts at Needham & Company LLC
www.americanbankingnews.com - April 26 at 11:24 AM |
Boston Scientific (NYSE:BSX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Boston Scientific (NYSE:BSX) Income Statement, Balance Sheet and Cash Flow Statement
Boston Scientific (NYSE BSX) Stock Chart for Sunday, May, 27, 2018
Loading chart…
